CD133+ cells in combination with human umbilical cord stem cells in mouse heart failure

doi:10.3969/j.issn.2095-4344.2016.14.013

Abstract

Abstract:

BACKGROUND: Currently, conventional treatment methods for heart failure are all ineffective.
OBJECTIVE: To explore the combined effects of human umbilical cord stem cells and CD133+ cells in mice with heart failure, providing a new insight into the treatment of heart failure.
METHODS: Full-term newborn umbilical cord from vaginal delivery was collected to isolate CD133+ cells and human umbilical cord stem cells using lymphocyte separation medium method. Twenty Balb/C nude mice were randomly subjected to mononuclear cell injection (mononuclear cell group) or injection of CD133+ cells combined with human umbilical cord stem cells (combined group) via the tail vein after establishing heart failure models.
RESULTS AND CONCLUSION: Fourteen days after injection, the body weight and liver, heart and lung mass of mice were significantly larger in the combined group than the mononuclear cell group (P < 0.05). After 30 days, myocardial cells arranged regularly in the combined group, but disorderly in the mononuclear cell group; compared with the mononuclear cell group, the average area of myocardial collagen fibers was significantly decreased in the combined group (P < 0.05), and the level of serum matrix metalloproteinase-9 was also significantly lower in the combined group (P < 0.05). Masson staining showed that blue-stained collagen fibers in the combined group were less but arranged neatly; however, in the mononuclear cell group, the number of collagen fibers that arranged irregularly was increased to different extents. To conclude, the combined use of CD133+ cells and human umbilical cord stem cells has desired outcomes in the treatment of heart failure in mice, indicating a higher clinical value.
中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

Key words: Heart Failure, Drug Therapy, Myocytes, Cardiac, Tissue Engineering

Hou Mei, Zhang Hong-xing, Ye Qing, Zhang Yong. CD133⁺ cells in combination with human umbilical cord stem cells in mouse heart failure[J]. Chinese Journal of Tissue Engineering Research, 2016, 20(14): 2066-2072.

Figures/Tables 4

References

[1] Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation. 2013;127(1): e6-e245.

[2] Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933-944.

[3] Domanski MJ, Krause-Steinrauf H, Massie BM, et al. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail. 2003;9(5): 354-363.

[4] Janssens S, Dubois C, Bogaert J, et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet. 2006; 367(9505): 113-121.

[5] 中华医学会心血管病学分会.中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):98-122.

[6] Wollert KC, Drexler H. Cell therapy for the treatment of coronary heart disease: a critical appraisal. Nat Rev Cardiol. 2010;7(4):204-215.

[7] Traverse JH, Henry TD, Pepine CJ, et al. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAMA. 2012;308(22):2380-2389.

[8] Perin EC, Willerson JT, Pepine CJ, et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA. 2012;307(16):1717-1726.

[9] 顾云,辛毅,吴永涛,等.参附注射液抑制大鼠缺血再灌注损伤期间心肌细胞凋亡的作用机制[J].新乡医学院学报, 2012, 29(2):85-88.

[10] 李丹,李蓓,石亚楠,等.心力衰竭与活性氧关系研究进展[J].中华实用诊断与治疗杂志,2013,27(1):8-10.

[11] Traverse JH, Henry TD, Ellis SG, et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA. 2011;306(19): 2110-2119.

[12] Huang XP, Sun Z, Miyagi Y, et al. Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation. 2010;122(23):2419-2429.

[13] Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308(22):2369-2379.

[14] 邱小华,戴育成,胡葵葵.脐带间充质干细胞的研究进展[J].中华临床医师杂志(电子版),2012,6(6):88-91.

[15] Ye L, Zhang S, Greder L, et al. Effective cardiac myocyte differentiation of human induced pluripotent stem cells requires VEGF. PLoS One. 2013;8(1): e53764.

[16] Chachques JC. Cellular cardiac regenerative therapy in which patients? Expert Rev Cardiovasc Ther. 2009; 7(8):911-919.

[17] Cortes-Morichetti M, Frati G, Schussler O, et al. Association between a cell-seeded collagen matrix and cellular cardiomyoplasty for myocardial support and regeneration. Tissue Eng. 2007;13(11):2681-2687.

[18] Perin EC, Willerson JT. CD34+ autologous human stem cells in treating refractory angina. Circ Res. 2011; 109(4):351-352.

[19] Losordo DW, Henry TD, Davidson C, et al. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res. 2011;109(4):428-436.

[20] Irollo E, Pirozzi G. CD133: to be or not to be, is this the real question? Am J Transl Res. 2013;5(6):563-581.

[21] Mizrak D, Brittan M, Alison M. CD133: molecule of the moment. J Pathol. 2008;214(1):3-9.

[22] Donovan LK, Pilkington GJ. CD133: holy of grail of neuro-oncology or promiscuous red-herring? Cell Prolif. 2012;45(6):527-537.

[23] Fargeas CA, Florek M, Huttner WB, et al. Characterization of prominin-2, a new member of the prominin family of pentaspan membrane glycoproteins. J Biol Chem. 2003;278(10):8586-8596.

[24] Barcelos LS, Duplaa C, Kränkel N, et al. Human CD133+ progenitor cells promote the healing of diabetic ischemic ulcers by paracrine stimulation of angiogenesis and activation of Wnt signaling. Circ Res. 2009;104(9):1095-1102.

[25] Pozzobon M, Bollini S, Iop L, et al. Human bone marrow-derived CD133(+) cells delivered to a collagen patch on cryoinjured rat heart promote angiogenesis and arteriogenesis. Cell Transplant. 2010;19(10): 1247-1260.

[26] 赵瑞刚,蔡俊彦,王军力.N端脑钠肽在心力衰竭诊治中的应用进展[J].河北医药,2013,35(2):268-270.

[27] 滕伟,薛永亮,何兆辉,等.磷酸肌酸钠对冠心病并慢性心力衰竭患者B型利钠肽及心功能的影响[J].中国医药导报, 2012,9(18):59-60.

[28] Fosbøl EL, Seibaek M, Brendorp B, et al. Long-term prognostic importance of resting heart rate in patients with left ventricular dysfunction in connection with either heart failure or myocardial infarction: the DIAMOND study. Int J Cardiol. 2010;140(3):279-286.

[29] Schroten NF, Ruifrok WP, Kleijn L, et al. Short-term vitamin D3 supplementation lowers plasma renin activity in patients with stable chronic heart failure: an open-label, blinded end point, randomized prospective trial (VitD-CHF trial). Am Heart J. 2013;166(2): 357-364. e2.

[30] Gheorghiade M, Böhm M, Greene SJ, et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA. 2013;309(11):1125-1135.

[31] 王辉,张知翠,罗晓菊,等.人脐血干细胞移植建立人鼠嵌合体动物模型实验研究[J].实用医院临床杂志,2008,5(4): 40-43.

[32] Strauer BE, Brehm M, Zeus T, et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation. 2002;106(15):1913-1918.

[33] 李丽,王明元,程根林,等.流式细胞术在成分血残留白细胞检测中的应用[J].临床输血与检验,2004,6(3):177-179.

[34] Romanic AM, Harrison SM, Bao W, et al. Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9. Cardiovasc Res. 2002;54(3):549-558.

[35] Li YY, McTiernan CF, Feldman AM. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res. 2000;46(2):214- 224.

[36] 徐赤裔,周建庆,方建江,等.干细胞移植治疗实验犬心肌梗死后心力衰竭的作用[J].浙江医学,2007,29(9):931-934.

[37] Qiao H, Zhang H, Zheng Y, et al. Embryonic stem cell grafting in normal and infarcted myocardium: serial assessment with MR imaging and PET dual detection. Radiology. 2009;250(3):821-829.

[38] 郝牧,漆佩静,李刚,等.人脐带间充质干细胞对脐血CD34~+细胞在NOD/SCID小鼠体内造血重建的影响[J].中国医学科学院学报,2010,32(1):71.

[39] 毛平,彭盘俐,许力.人脐血单个核细胞体外扩增后植入NOD/SCID小鼠重建多系造血[J].中华器官移植杂志, 2006,27(4):231-234.

[40] 谭玲,陈勇华,张春明,等.人脐血CD133细胞的分离及其体外扩增的研究[J].现代生物医学进展,2007,7(6): 853-856.

[41] 车京津,张承宗,陈元禄,等.缬沙坦、苯那普利及合用时对心肌梗死后心室重构影响的比较[J].中国心血管杂志, 2002,7(6):381-384.

[42] 张军霞,李瑞,赵鹏,等.CD133免疫磁珠分选脐血内皮祖细胞的培养及鉴定[J].中国肿瘤生物治疗杂志,2008, 15(2):159-162.

[43] Beier D, Hau P, Proescholdt M, et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007;67(9):4010-4015.

[44] 吴计生,段淑云,郝建平.免疫组化抗原修复的应用进展[J].实用医技杂志,2006,13(20):3592-3593.

[45] 康文慧,马元,罗明.两种剂量异丙肾上腺素制备心衰大鼠模型心功能的比较[J].同济大学学报(医学版),2009,30(4): 50-53.

[46] 冯清华,张晶.心理干预联合药物治疗老年慢性心力衰竭患者疗效观察[J].中国循证心血管医学杂志,2011,3(4): 295-296.

[47] 中国康复医学会心血管病专业委员会,中国老年学学会心血管病专业委员会.慢性稳定性心力衰竭运动康复中国专家共识[J].中华心血管病杂志,2014,42(9):714-720.

[48] Freyssin C, Verkindt C, Prieur F, et al. Cardiac rehabilitation in chronic heart failure: effect of an 8-week, high-intensity interval training versus continuous training. Arch Phys Med Rehabil. 2012;93(8):1359-1364.

[49] 沈玉芹,蒋金法,王乐民,等.有氧运动康复对慢性心力衰竭患者运动心排血量及相关参数的影响[J].中华心血管病杂志,2011,39(8):700-705.

[50] 陈巍,林平,李玲.中文版心力衰竭患者自我护理行为量表的信效度检测[J].中华护理杂志,2013,48(7):629-631.

[51] 党海舟,李明凯,徐明,等.主动脉弓缩窄术和腹腔注射IPH致小鼠慢性心衰两种模型的比较和评价[J].心脏杂志, 2012,24(2):168-172.

[52] 孙晓靖.他汀类药物对异丙肾心衰大鼠心肌细胞凋亡影响的研究[D].乌鲁木齐:新疆医科大学,2009.

[53] Koutna I, Peterkova M, Simara P, et al. Proliferation and differentiation potential of CD133+ and CD34+ populations from the bone marrow and mobilized peripheral blood. Ann Hematol. 2011;90(2):127-137.

[54] 谢亚序,康大伟,李秀华.慢性心力衰竭心肌纤维化大鼠模型的建立[J].承德医学院学报,2011,28(1):10-12.

[55] To LB, Haylock DN, Dowse T, et al. A comparative study of the phenotype and proliferative capacity of peripheral blood (PB) CD34+ cells mobilized by four different protocols and those of steady-phase PB and bone marrow CD34+ cells. Blood. 1994;84(9):2930-2939.

[56] Freund D, Oswald J, Feldmann S, et al. Comparative analysis of proliferative potential and clonogenicity of MACS-immunomagnetic isolated CD34+ and CD133+ blood stem cells derived from a single donor. Cell Prolif. 2006;39(4):325-332.

[57] Charrier S, Boiret N, Fouassier M, et al. Normal human bone marrow CD34(+)CD133(+) cells contain primitive cells able to produce different categories of colony-forming unit megakaryocytes in vitro. Exp Hematol. 2002;30(9):1051-1060.

[58] Menasche P. Cardiac cell therapy: lessons from clinical trials. J Mol Cell Cardiol. 2011;50(2):258-265.

[59] Minami I, Yamada K, Otsuji TG, et al. A small molecule that promotes cardiac differentiation of human pluripotent stem cells under defined, cytokine- and xeno-free conditions. Cell Rep. 2012;2(5):1448-1460.

[60] Fonoudi H, Ansari H, Abbasalizadeh S, et al. A Universal and Robust Integrated Platform for the Scalable Production of Human Cardiomyocytes From Pluripotent Stem Cells. Stem Cells Transl Med. 2015; 4(12):1482-1494.

[61] Willems E, Spiering S, Davidovics H, et al. Small-molecule inhibitors of the Wnt pathway potently promote cardiomyocytes from human embryonic stem cell-derived mesoderm. Circ Res. 2011;109(4): 360-364.

[62] Lian X, Hsiao C, Wilson G, et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci U S A. 2012;109(27):E1848-1857.

[63] Lian X, Zhang J, Azarin SM, et al. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/β-catenin signaling under fully defined conditions. Nat Protoc. 2013;8(1): 162-175.

[64] Frank S, Zhang M, Schöler HR, et al. Small molecule-assisted, line-independent maintenance of human pluripotent stem cells in defined conditions. PLoS One. 2012;7(7):e41958.